logo

For the Inventor, By the Inventor

Yokohama, Japan

Masaharu Shiotani

This inventor holds 6 USPTO granted patents. Top assignee: Meiji Seika Kaisha, Ltd.. Active years: 2002-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masaharu Shiotani. Retrieved from https://idiyas.com/inventor/masaharu-shiotani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6

% Patents Active = 33.3

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 39(Granted Patents)


Company Filing History:

goldMedal6 out of 382 
 
Meiji Seika Kaisha, Ltd.
 patents

Years Active: 2002-2006

Loading Chart...
6 patents (USPTO):Explore Patents
1. 7030120 - Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same (2006-04-18),
2. 6777414 - Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same (2004-08-17),
3. 6583144 - Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same (2003-06-24),
4. 6440951 - Method for treatment of diabetes (2002-08-27),
5. 6417362 - Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same (2002-07-09),
6. 6413946 - Composition for treatment of diabetes and treatment of diabetes (2002-07-02),

Title: The Innovative Contributions of Masaharu Shiotani

Introduction

Masaharu Shiotani is a prominent inventor based in Yokohama, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target lipid metabolism. With a total of six patents to his name, Shiotani's work is recognized for its potential impact on treating hyperlipidemia and arteriosclerotic diseases.

Latest Patents

Shiotani's latest patents include innovative nitrogen-containing heterocyclic compounds and benzamide compounds. These compounds are designed to inhibit triglyceride biosynthesis in the liver and reduce the secretion of apolipoprotein B-containing lipoproteins. The compounds are notable for their effectiveness without the side effect of lipid accumulation in the liver, making them valuable for the treatment and prevention of various metabolic disorders.

Career Highlights

Throughout his career, Masaharu Shiotani has been associated with Meiji Seika Kaisha, Ltd., a company known for its commitment to research and development in the pharmaceutical industry. His work has contributed to advancements in drug formulations and therapeutic strategies.

Collaborations

Shiotani has collaborated with notable colleagues, including Naoto Ohkura and Yukiko Hiraiwa. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Masaharu Shiotani's contributions to pharmaceutical innovation highlight the importance of research in developing effective treatments for metabolic diseases. His work continues to influence the field and offers hope for improved health outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…